Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study

Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study

Background: Treatment for HER2-positive (+) metastatic breast cancer has improved in the last decade. We analyzed treatment changes over time and their impact on patients outcomes in a real-world dataset. Methods: Data from 637 HER2+ patients with metastatic breast cancer enrolled in the multicenter...

Full description

Bibliographic Details
Main Authors: Massimo Di Maio, Claudia Bighin, Francesco Schettini, Tommaso Ruelle, Laura Marandino, Alessandra Fabi, Carmine De Angelis, Mario Giuliano, Pietro De Placido, Michelino De Laurentiis, Ferdinando Riccardi, Caterina Picotto, Fabio Puglisi, Lucia Del Mastro, Grazia Arpino
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Breast
Subjects:
Breast cancer
HER2-Positive
Metastasis
First line of therapy
Trastuzumab
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977623005593

Internet

http://www.sciencedirect.com/science/article/pii/S0960977623005593

Similar Items